Nasdaq cuts target to USD 13.89 for VolitionRx stock
Published on 10/16/2026 at 03:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget revision and diagnostic launch
- The average target fell from USD 16.83 to USD 13.89 on October 2, 2026.
- VolitionRx reported USD 398,000 of revenue in the second quarter of 2026.
- The company launched its DETECSEPS program in France on September 17, 2026.
VolitionRx cut its average one-year target from USD 16.83 to USD 13.89 on October 2, 2026, according to Nasdaq. VolitionRx stock was last quoted at USD 0.19 on the NYSE American on October 15, 2026 at 4:00 p.m. EDT.
Target reset highlights risk
The revised average target represents a 17.44 percent reduction from the prior estimate. The Nasdaq report said the latest targets ranged from USD 2.02 to USD 25.20 per share, underscoring the wide dispersion in expectations.
The latest reported quarter also showed a difficult operating profile. VolitionRx generated USD 398,000 of revenue in the second quarter of 2026, below the USD 492,323 consensus estimate, while adjusted earnings per share came in at minus USD 0.85 against an estimate of minus USD 0.5855, according to Nasdaq.
What changed during September
VolitionRx announced the full prepayment of a USD 7.5 million senior secured convertible promissory note on September 14, 2026, according to VolitionRx. Three days later, the company participated in the launch of its DETECSEPS program in France, also listed on the investor-relations page.
The chronology matters because the financing step and the French launch point to different investor questions. Debt reduction addresses near-term balance-sheet pressure, while DETECSEPS provides a commercial and clinical development milestone for the diagnostic platform.
Which dates matter next
MarketBeat lists November 12, 2026 as the estimated next earnings date. The company reported its second-quarter results on August 13, 2026, for the quarter ended June 30, 2026.
Stock stays tied to execution
MarketBeat lists a USD 2.57 million market capitalization and a 52-week range of USD 0.17 to USD 10.31. Those figures place the target revision beside a very small equity value and a broad trading history, making operating execution central to the valuation debate.
The next report will show whether revenue can build beyond the USD 398,000 second-quarter base and whether the French program adds commercial evidence.
VolitionRx stock key data
- Company: VolitionRx Ltd
- ISIN: US9286612067
- Ticker: VNRX
- Primary exchange: NYSE American
- Latest primary-exchange price: USD 0.19 as of October 15, 2026, 4:00 p.m. EDT
- Market capitalization: USD 2.6 million as of October 15, 2026
- 52-week range: USD 0.17-10.31
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report S&P 500.
